Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.
You may also be interested in...
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.
Panel’s Split Decision On Dyax HAE Drug Belies Consensus On Clinical Data
Advisory panel concerned with limited efficacy and safety data; members express uncertainty over standards for orphan drug approval.